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ABSTRACT
Introduction: Fifty years after the discovery of Δ9-tetrahydrocannabinol (THC) as the psychoactive
component of Cannabis, we are assessing the possibility of translating this herb into clinical treatment
of inflammatory bowel diseases (IBDs). Here, a discussion on the problems associated with a potential
treatment is given. From first surveys and small clinical studies in patients with IBD we have learned
that Cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite. Single
ingredients from Cannabis, such as THC and cannabidiol, commonly described as cannabinoids, are
responsible for these effects. Synthetic cannabinoid receptor agonists are also termed cannabinoids,
some of which, like dronabinol and nabilone, are already available with a narcotic prescription.
Areas covered: Recent data on the effects of Cannabis/cannabinoids in experimental models of IBD
and in clinical trials with IBD patients have been reviewed using a PubMed database search. A short
background on the endocannabinoid system is also provided.
Expert commentary: Cannabinoids could be helpful for certain symptoms of IBD, but there is still a lack
of clinical studies to prove efficacy, tolerability and safety of cannabinoid-based medication for IBD
patients, leaving medical professionals without evidence and guidelines.
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Inflammatory bowel diseases (IBDs), i.e. Crohn’s disease (CD)
and ulcerative colitis (UC), are chronic inflammatory conditions
of the gastrointestinal (GI) tract with increasing prevalence in
Westernized countries [1]. Although their etiology is still
unknown, these diseases are thought to comprise misdirected
attacks of the immune system against gut microbiota or their
products [2]. Defects in the epithelial barrier function and in
mucosal wound healing are of paramount importance in the
progression of IBD [1,2]. The endocannabinoid system (ECS)
has been recognized to play an important role in the main-
tenance of gut homeostasis since it quickly responds to dis-
turbances by de novo synthesis of its effector molecules and is,
therefore, of particular interest in the management of IBD [3].
The ECS consists of lipid mediators, so-called endocan-
nabinoids, their synthesizing and degrading enzymes, and
of G protein-coupled cannabinoid receptors (CBs) that
mediate the endocannabinoid effects (Figure 1).
Components of the ECS have been found to be expressed
throughout the GI tract and have been reviewed in detail
elsewhere [4,5]. Briefly, the ECS has been described to
comprise two CBs, i.e. cannabinoid receptor 1 (CB1) and 2
(CB2). CBs can be activated by a variety of synthetic or
plant-derived cannabinoids, as well as by the endocanna-
binoids anandamide (arachidonoylethanolamine [AEA])
and 2-arachidonoylglycerol (2-AG). Synthesizing enzymes
include N-acyl phosphatidylethanolamine phospholipase D
(NAPE-PLD) for AEA and diacylglycerol lipase for 2-AG,
respectively.
Degradation of AEA is facilitated mainly by fatty acid
amide hydrolase (FAAH), whereas 2-AG is degraded mostly
by monoacylglycerol lipase (MGL or MAGL). However, the
notion of the ECS being a confined physiological entity
with CB receptors in its center has been challenged by
the discovery of receptors responsive to cannabinoids
other than CB1/2, such as G protein-coupled receptor 55
(GPR55), transient receptor potential of vanilloid-type 1
(TRPV1), and peroxisome proliferator-activated nuclear
receptors (PPARs) [6]. Furthermore, it has been found that
the ECS does not only consist of the aforementioned bio-
synthetic and degrading components, but also in fact
shares many enzymes with other pathways, e.g. cyclooxy-
genase-2 which oxidizes AEA and thus provides a link
between the ECS and prostaglandin synthesis [7]. While
the complexity of the interactions of all molecules involved
in (endo-) cannabinoid signaling represents a large obsta-
cle in understanding the endocannabinoids’ role in (patho-
)physiology, research on the ‘expanded ECS’ or ‘endocan-
nabinoidome’ [7] may very well open doors for new treat-
ment options. After all, it is desirable to discover
cannabinoid based drugs that exert their actions without
causing psychotropic effects that arise from activation of
central CB1 receptors.
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2. The ECS as a therapeutic target in IBD
To investigate the role of cannabinoids in IBD, mostly animal
models that rely on chemically induced mucosal inflammation
are used. Dextran sulfate sodium (DSS)-induced colitis, for
instance, causes the influx of macrophages, neutrophils, and
a Th2-mediated immune response [8–10], whereas trinitroben-
zene sulfonic acid (TNBS)-induced colitis is more dominated by
a Th1-response [8,10]. Analysis of expression levels of ECS
components in inflamed rodent colonic tissue revealed
enhanced cannabinoid signaling under inflammatory condi-
tions as compared to healthy tissue. Thus, CB1 and CB2 recep-
tors, as well as AEA, were found to be upregulated in
experimental IBD models [11,12]. Upregulation of AEA, how-
ever, was only found in certain layers of the colon (e.g. in the
submucosa but not the mucosa) [11]. On the other hand, the
AEA-degrading enzyme FAAH was expressed to a lesser extent
in the initial stage of colitis but returned to control levels as
the disease progressed [13]. Pharmacological strategies to
enhance endocannabinoid levels in the inflamed colon of
rodents through inhibition of the degrading enzymes FAAH
or MGL, respectively, ameliorated the inflammation [14,15].
Accordingly, it has been reported that activation of CB1 or
CB2 with synthetic agonists protected from colitis [12,16] and
that treatment with Δ9-tetrahydrocannabinol (THC), the main
psychoactive constituent of Cannabis sativa, reduced TNBS-
induced inflammation as well as myeloperoxidase (MPO) activ-
ity and motility disturbances in the in rat colon [17]. These
findings prompted the investigation of other nonpsychoactive
components of Cannabis in IBD models. It has been shown
that cannabidiol (CBD), a cannabinoid with very low affinity for
CB1 and CB2, has protective effects in murine colitis as
observed by a reduction of colon injury, inducible nitric
oxide synthase expression, reactive oxygen species produc-
tion, MPO activity, and tumor necrosis factor alpha (TNF-α)
levels [17–21]. CBD has also been reported to inhibit FAAH
activity [22] and could thus alter endocannabinoid levels.
Other non-psychotropic cannabinoids, shown to be beneficial
in colitis models, include the plant cannabinoid cannabigerol
[23] and the synthetic atypical cannabinoid O-1602, which has
been shown to inhibit neutrophil recruitment [24].
Cannabigerol reduced nitric oxide production in macrophages
and this effect was modulated by the CB2 receptors [23]. While
the molecular targets of cannabigerol and O-1602 have not
been fully elucidated yet, extensive evidence exists that CBD
exerts its functions, at least partly, through PPARs [21]. CBD
has also been reported to act as an antagonist to GPR55, a
receptor that plays a crucial role in intestinal inflammation
[25]. Another molecule of interest in IBD is palmitoylethanola-
mide (PEA), a structural relative of anandamide that acts via
multiple targets including CB1, CB2, GPR55, PPARα, and TRPV1
and that has been reported to reduce inflammation and
intestinal permeability in mice [26–28]. With regard to the
ECS, beneficial effects of PEA in experimental IBD involved
an increase in colonic CB1 receptor expression and activation
of CB2 and GPR55 [26]. Another plant cannabinoid with anti-
inflammatory properties in murine colitis is cannabichromene
[29] which inhibited endocannabinoid inactivation [30].
Taken together, a huge amount of preclinical data strongly
support the ECS as a therapeutic target in IBD (as previously
reviewed by Refs. [3,31–33]).
2.1. Components of the ECS are differentially expressed
in human IBD
The altered regulation of the ECS in IBD patients has been
addressed in various reports with rather contradictory out-
comes (summarized in Table 1). Although AEA levels were
found to be increased in UC patients (n = 8) [11], some studies
reported an overall reduced AEA signaling in IBD patients, as
observed through decreased activity and/or levels of the
synthesizing enzyme NAPE-PLD [34,35], as well as through
increased activity of the degrading enzyme FAAH [34,35],
and through reduced levels of AEA [34]. Enhanced CB2 immu-
noreactivity has been observed in the colonic epithelium and
Figure 1. A schematic overview of cannabinoid receptors, cannabinoid-responsive non-cannabinoid receptors, their ligands and degrading enzymes of the
endocannabinoid system as described in murine IBD. 2-AG, 2-arachidonoylglycerol; AEA, anandamide; CB, cannabinoid receptor; CBD, cannabidiol; FAAH, fatty
acid amide hydrolase; GPR55, G protein-coupled receptor 55; NAAA, N-acylethanolamine-hydrolyzing acid amidase; PEA, palmitoylethanolamide; PPARs, peroxisome
proliferator-activated nuclear receptors; THC, Δ9-tetrahydrocannabinol; TRPV1, transient receptor potential of vanilloid-type 1.
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some cells of the inflammatory cell infiltrate in CD and UC
specimens, suggesting that CB2 might be a relevant target for
IBD treatment [34–36]. In fact, activation of CB2 has shown
protection in experimental models of colitis [16,37]. Also in a
human colonic explant model, where colitis-like damage was
induced with pro-inflammatory cytokines, activation of CB2 led
to reduced damage of mucosal crypts and the epithelial lin-
ing [38].
Furthermore, treatment with methanandamide, a non-
hydrolysable analog of AEA, reduced interferon-γ and TNF-α
secretion from cultured biopsy specimens and from lamina
propria cells isolated from IBD specimens [34].
2.2. Could Cannabis be used as a treatment for IBD?
Thousands of years ago, Cannabis was traditionally used for
the treatment of inflammation of the gut. Nowadays, the use
of medicinal Cannabis is being legalized in a growing num-
ber of countries but clinical studies on the effects of
Cannabis in IBD are scarce. Questionnaires conducted in
Canada, USA, and Israel so far revealed that patients com-
monly use the drug as a self-medication to relieve IBD-
related symptoms, including abdominal pain, diarrhea, and
loss of appetite [39–43]. A retrospective observational study
on 30 patients with CD found that 21 subjects significantly
benefited from Cannabis consumption as seen through a
significant reduction of the average Harvey Bradshaw Index
as well as through a reduced need for other medication [44].
A prospective pilot study with 13 IBD patients, who were
instructed to inhale Cannabis when they were in pain, con-
cluded that the treatment significantly improved the
patients’ quality of life [42]. Finally, a small randomized
placebo-controlled clinical trial suggested beneficial effects
of Cannabis treatment in CD patients [45]. In this study, 11
patients received Cannabis cigarettes containing 115 mg
THC twice daily, while the placebo group (n = 10) received
Cannabis flowers that were devoid of THC. The duration of
the study was 8 weeks with an additional wash out phase of
2 weeks. Because of the small sample sizes, a statistical
difference in remission (a Crohn’s disease and activity index
[CDAI] < 150) between treatment (5/11) and placebo group
(1/10) was not achieved. A clinical response (a reduction in
CDAI > 100), however, was observed in 10/11 subjects in the
treatment group (4/10 in the placebo group). Additionally, in
the Cannabis group, three patients were weaned from ster-
oids and two from opiates. Patients of the treatment group
further reported an increase in quality of life (as assessed by
SF-36). A difference in objective markers of inflammation, i.e.
C-reactive protein, however, was not observed between the
two groups [45]. A summary of clinical studies on the benefit
Table 1. Differential expression of ECS components in human IBD compared to controls as described in the literature.
IBD
ECS component UC CD References
Receptors CB1 No change, downregulation, or upregulation Upregulation [26–28]
CB2 Upregulation [27,30]
Upregulation (protein) or no change (mRNA, protein) [26,28]
Ligands AEA Upregulation [10]
Downregulation [26]
2-AG No change [10,26]
Synthesizing enzymes NAPE-PLD Downregulation or reduced activity [26,27]
DAGL Upregulation [27]
Degrading enzymes FAAH No change (epithelium) or upregulation (immune cells) or increased activity [26,27]
MGL Upregulation [27]
CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2; AEA: anandamide; 2-AG: 2-arachidonoylglycerol; ECS: endocannabinoid system; IBD: inflammatory bowel disease;
NAPE-PLD: N-acyl phosphatidylethanolamine phospholipase D; DAGL: diacylglycerol lipase; FAAH: fatty acid amide hydrolase; MGL: monoacylglycerol lipase.
Table 2. An overview of clinical studies on Cannabis treatment in IBD patients.
Patient
number (n)
Study type UC CD Treatment Investigated parameters Findings Reference
Questionnaire 100 191 – Cannabis use, SIBDQ 33% of UC and 50% of CD patients used
Cannabis for symptom relief
[31]
Questionnaire 63 231 – Cannabis use, subjective
assessment, users vs. nonusers
17.6% of patients used Cannabis for





– 30 Cannabis use (unspecified) HBI, need for surgery and
hospitalization
HBI reduced from 14 ± 6.7 to 7 ± 4.7 [36]
Prospective study 2 11 Cannabis use for 3 months
(not standardized)
HBI, partial Mayo score HBI reduced from 11.36 ± 3.17 to 5.72 ± 2.68 [34]
Prospective study – 21 115 mg THC twice daily or
placebo for 8 weeks
CDAI, life quality (SF-36) Remission (5/11), CDAI reduction (10/11),
increased life quality
[37]
Prospective survey 102 177 – Cannabis use 16.4% of patients used Cannabis for
symptom relief
[32]
Prospective survey 18 35 – Cannabis use, SIBDQ in young
adults
45% of patients (18–21 years old) used
Cannabis for symptom relief
[35]
HBI: Harvey Bradshaw index; IBD: inflammatory bowel disease; THC: Δ9-tetrahydrocannabinol; CDAI: Crohn’s disease and activity index; SIBDQ: short-inflammatory
bowel disease questionnaire.
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of Cannabis medication in IBD conducted to date is given in
Table 2. It should be kept in mind, however, that most of
these clinical studies are statistically underpowered and also
lack methodological quality. Another critical point is the use
of the right placebo in these studies as central effects of
Cannabis/cannabinoids are hard to conceal.
2.3. CBD for the treatment of IBD?
As outlined above, several preclinical studies have indi-
cated that CBD is protective in intestinal inflammation
[17–20]. A study in an lipopolysaccharide-induced model
suggested that CBD, which is known to act as GPR55
antagonist [46], inhibits GI inflammation by controlling
the inflammatory response and the activation of enteric
glial cells [21]. Parts of the beneficial effects by CBD were
mediated via PPARγ raising the possibility that GPR55 could
have been involved in the beneficial effect [21].
Furthermore, CBD could be supportive in maintaining a
healthy intestinal barrier. In a CaCo-2 cell monolayer
model stimulated by EDTA, CBD recovered the intestinal
barrier in a concentration and CB1-dependent manner [47].
The results of a clinical trial on CBD in IBD (ClinicalTrials.
gov ID NCT01037322), however, have not been published
so far. The anti-inflammatory potential of CBD has been
also recently reviewed elsewhere [48].
3. Conclusion
Experimental evidence gathered from preclinical IBD mod-
els and conducted in rodents point to a strong potential of
the ECS components to serve as drug targets in inflamma-
tory diseases of the intestine. Data suggest a homeostatic
role of the ECS in the gut. Accordingly, it is believed that
the enhancement of endocannabinoid signaling, as
observed through the increased levels of endocannabi-
noids and their receptors, and the decrease in endocanna-
binoid degrading enzymes, is a response to disturbances of
the homeostatic system and is aimed at restoring the
balance. This is further supported by the finding that the
manipulation of the ECS toward a further increase of
endocannabinoid signaling is protective against IBD. On
the other hand, analysis of biopsies from UC and CD
patients paints a rather complex picture in terms of differ-
ential expression of ECS components. Most likely, owing to
the small sample sizes in the studies, a conclusion on the
meaning of this has not yet been reached. Most evidence
points toward an involvement of CB1 and also CB2 recep-
tors, especially with regard to immune cell recruitment.
Further research in this direction, preferably on human
IBD material, such as explants, cultured biopsies, etc. is
highly warranted.
4. Expert commentary
IBDs pose a high burden on patients and health-care systems
alike. Current therapy includes anti-inflammatory agents like
aminosalicylic acid, immunomodulators, steroids, and
biological agents, such as anti-TNF-α antibodies and vedolizu-
mab (an anti-α4β7 integrin antibody that specifically targets
adhesion and migration of leukocytes to the GI tract) [49].
Vedolizumab has shown its ability and effectiveness in the
induction therapy of IBD, in particular, in patient’s refractory
to anti-TNF-α antibody treatment [50]. Biologicals are first-line
alternative treatment options in severe IBD and are powerful
tools to change the course of the disease [49,51]. However,
they come at the prize, as in the case of anti-TNF-α antibodies,
of causing severe adverse effects, such as infections, malig-
nancies, and injection/infusion reactions [52]. For
Vedolizumab, cases of arthritis and sarcoiliitis have been
recently reported [53]. Conventional treatment is often little
effective leaving many patients dissatisfied [54]. Because of
failing standard therapy, willingness and desire of IBD patients
to use complementary and alternative medicine (CAM) are
understandably high and an alternative treatment with
Cannabis is, therefore, often sought.
Not surprisingly, a New Zealand Survey of 1370 patients
with IBD revealed that 44.1% of IBD patients self-medicated
with CAM, including Cannabis [55]. Additionally, a large popu-
lation-based study, using data from the NHANES database
(National Center for Health Statistics) showed that IBD patients
had a higher incidence (67.3% vs. 60.0%) and an earlier onset
in age (15.7 vs. 19.6 years) for Cannabis use as compared to
control subjects [56]. Judging from these data, Cannabis has
long been used by IBD patients as a form of ‘self-treatment’ to
control their symptoms. In the US prospective cohort survey of
IBD patients, Ravikoff Allegretti reported that half of the
patients, who had never used Cannabis before, expressed
their interest in Cannabis for treatment, in particular, against
abdominal pain [40].
The broad interest for alternative medicine often puts med-
ical professionals in a situation in which patients express their
wish to use Cannabis medicinally, but at the same time, they
also face legal and administrative boundaries for its prescrip-
tion. Unlike in Canada, Israel, and some states in the United
States, ‘medical marijuana’ is not legally available in most
European countries (only after seeking permission from the
government) although cannabinoid-based drugs, such as
nabiximols (Sativex®), dronabinol, and nabilone, can be
obtained (Table 3). Prescription of these drugs has to follow
strict indications or may be given off-label with a narcotic
prescription, a situation many physicians are reluctant to
deal with.







Nabiximols (combination of THC and cannabidiol)
Application: sublingual spray
Trade name: Sativex®
Medical Marijuana (dried leaves and buds from Cannabis)
Application: oral, by inhalation, topical
Traded as ‘Medical Marijuana’ or ‘Medical Cannabis’
THC: Δ9-tetrahydrocannabinol.
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4.1. Basic versus clinical research with Cannabis/
cannabinoids
A surge of preclinical data on cellular mechanisms of CB
receptors and other components of the ECS have recently
come forward. However, more information on in vivo mechan-
isms of cannabinoids and the ECS in inflammatory diseases
like IBD is necessary, despite existing reports [19–
21,23,25,26,57]. Although we can assume that anti-inflamma-
tory actions of cannabinoids employ peripherally as well as
centrally located CB receptors [58,59], a broader picture on
how cannabinoids improve severity of inflammation in IBD is
needed. Most likely, the ECS concerts a holistic anti-inflamma-
tory response linking endocannabinoids with CB receptors and
non-CB1/CB2 cannabinoid-responsive receptors, such as GPR55
[25] and PPARα [26]. Thus, the ECS exerts profound effects on
the GI-immune system, intestinal barrier, motility, and brain
areas that control gut homeostasis [58].
As to clinical research, data on human trials with Cannabis/
cannabinoids in IBD unfortunately lag behind. The medical prac-
titioner has no evidence or guidelines when confronted with
questions whether and how to use Cannabis/cannabinoids for
the treatment of IBD. Exactly this is of critical importance as the
general public is becoming increasingly interested in trying
medical treatment with Cannabis. With the availability of medical
marijuana and the lack of guidelines for treatment, people may
tend to apply Cannabis with the help of a whole range of
unprofessional advice and views, an extremely undesirable
situation.
4.2. Clinical evidence, efficacy, and safety of
cannabinoid-based treatment in IBD
Evidence that Cannabis/cannabinoids provide benefit for IBD
patients is still sparse. Apart from anecdotal reports and some
small clinical trials [42,44,45], as well as a handful of question-
naires [39–41,43], not much is known regarding a benefit for
IBD patients by Cannabis. After reviewing the small amount of
literature available on Cannabis/cannabinoids and human IBD,
some indication can be seen for the use of Cannabis against
abdominal pain, nausea, and loss of appetite in CD but treat-
ment should only be considered after careful assessment of
risks and after failure of standard medication. With regard to
UC, indication that Cannabis may provide benefit for patients
mainly derives from anecdotes and surveys [39–41].
Altogether, clinical trials are urgently warranted to determine
the efficacy of Cannabis/cannabinoids in IBD and to draw a
comprehensive conclusion. Cannabis/cannabinoids have been
considered generally safe as a short-time medication for adults
but as a meta-review recently pointed out, there is also a risk
of serious adverse events in short-term treatment [60]. High
odds for side effects include psychiatric, nervous system, and
hepatobiliary disorders; however, short-term treatment mostly
causes not only dry mouth, dizziness, somnolence, euphoria,
but also hallucinations [60]. These psychotropic-adverse
effects are caused by activation of CB1 receptors in the brain.
A possibility to circumvent this obstacle could be the use of
cannabinoids that do not enter the blood–brain barrier or that
only act peripherally.
4.3. Risks of long-term treatment with Cannabis/
cannabinoids in IBD
Many questions arise when considering long-term treatment
with Cannabis/cannabinoids which is likely necessary in dis-
eases like IBD. Long-term treatment is a strong caveat in
adolescent people, given the young age of 20 years for the
onset of CD [61]. Prolonged use of Cannabis has shown
neurological changes in adolescents including a decrease
in gray matter volume in certain brain areas [62]. This aspect
needs close attention because a new survey in young adults
with IBD (from 18 to 21 years) reported that 70% of these
patients did not discuss marijuana use with their gastroen-
terologist and only half of them had knowledge of possible
adverse effects [43]. A further aspect to be considered when
using Cannabis for medical treatment is pregnancy. A recent
study suggests an increase in stillbirth by long-term use of
Cannabis [63]. Since IBD is frequently accompanied by
comorbidities, such as cardiovascular disease [64], patients
taking Cannabis should be aware of the risk of myocardial
infarction and stroke [65].
Long-term treatment with Cannabis/cannabinoids may also
have pronounced effects on gut permeability. While THC and
CBD have shown permeability-preserving and CB1-dependent
properties in CaCo-2 monolayers, the opposite was observed
for the endocannabinoids AEA and 2-AG [47,66]. Treatment
with FAAH inhibitors that raise endocannabinoid levels may
therefore unfavorably affect gut leakiness that is associated
with IBD. To minimize risks of adverse effects by cannabinoids,
which are caused by activation of CB1 receptors in the brain,
the CB2 receptor may be an alternative and valuable target to
treat IBD. Unlike with the CB1 receptor, activation of CB2 does
not lead to psychotropic effects. In addition, experimental
data point to a crucial role of CB2 in the protection against
colitis [16,37]. New compounds have been recently described
as selective CB2 agonists capable of ameliorating inflammation
during DSS colitis [67] but it remains to be evaluated whether
CB2 agonists are also anti-inflammatory in human IBD.
4.4. Application of Cannabis/cannabinoids in IBD
Medical marijuana is preferably applied via inhalation.
Bioavailability levels of THC average at about 30% [68]. Oral
THC has been shown to be effective in chemotherapy-induced
nausea at a dose of 5–15 mg/m2 [69]. Most variabilities in THC
bioavailability are due to the individual itself and the different
content of THC in marijuana plants, a general problem of
phytotherapy [68]. These obstacles can be circumvented by
using purified ingredients of Cannabis or combinations of
purified ingredients, as in nabiximols (THC and CBD), which
is applied as a sublingual spray. Each milliliter of nabiximols
contains 27 mg THC and 25 mg CBD and a meta-review
summarized that the most common maximum dose was 8
sprays/3 h or 48 sprays/24 h in studies of spasticity, pain,
nausea, and vomiting [60]. A possibility for IBD patients to
undergo treatment with Cannabis/cannabinoids may be by
intrarectal (IR) application. Preclinical studies in mice have
shown an anti-inflammatory effect after IR application of
CBD [18]. The IR route could reduce first pass effects and
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would allow cannabinoids to act also locally at receptors of
the ECS which is highly represented in the bowel mucosa [35].
Doses of CBD have been evaluated in clinical studies of psy-
chosis and anxiety and range between 200 and 800 mg/d [60].
Most common doses for dronabinol and nabilone were
5–30 mg/d (1–2 doses/d) and 2 mg 2× d, respectively, in
studies of spasticity, pain, nausea, and vomiting [60].
5. Five-year view
Since the beginning of cannabinoid research, which is marked
by the cloning of the CB1 receptor [70], the field has rapidly
expanded, in particular, during the past decade. In 2011, the
search term ‘cannabinoid’ yielded over 7000 hits in PubMed,
the US National Library of Medicine, while this number has
soared above 20,000 in 2016. However, for the gastroenterol-
ogist, it is sobering to realize that not even a 100 hits pop up
when using the terms ‘cannabinoid’ and ‘inflammatory bowel
disease'.
With increasing interest of the public and the attention of
funding agencies, this will hopefully change in the years to
come. By implementation of clinical trials on Cannabis/canna-
binoids in IBD and the search for potential mechanisms of
action in humans, the topic will certainly shift into the focus
of the research community. On the preclinical side, we will
gain more information on relevant basic mechanisms of can-
nabinoids in experimental IBD, for instance, on the role of CB
receptors in the interaction of the microbiome with the gut
epithelial barrier [71]. Although preliminary data on the effi-
cacy of CBD in human CD do not appear to be promising [72],
CBD still may find a way into treatment of IBD, after carefully
evaluating dose and mode of application. From experimental
data, FAAH inhibitors could hold high promise in the treat-
ment of IBD [14,73,74]. However, human trials have failed to
provide efficacy of these inhibitors [75]. In addition, the tragic
incidence during the phase I trial for the FAAH inhibitor BIA
10-2474 has now hampered the translation of these drugs into
humans, although up to that incident, other FAAH inhibitors
were generally safe in human trials [76,77]. Here, we may have
to come back to preclinical research to better understand the
(patho-)physiological role of FAAH, and the mechanisms and
caveats of these inhibitors.
The future will shed more light on drugs that directly target
enzymes of the ECS to raise levels of endocannabinoids and
other lipid compounds, such as PEA. Thus, exogenous PEA has
been shown to reduce severity of experimental colitis [26].
Levels of PEA can be also increased endogenously in the
colon via inhibition of N-acylethanolamine-hydrolyzing acid
amidase leading to an improvement of experimental inflam-
mation of the colon [27]. Certainly, inhibitors of MGL that raise
endogenous levels of 2-AG will be in the focus during the
years to come. IBD patients could benefit from such drugs
through their antinociceptive and anti-inflammatory potential
[78]. On the clinical side, we expect to see an increase in
clinical studies (observational, controlled, and prospective)
evaluating the efficacy of cannabinoid compounds in IBD.
Some of the key questions are not answered yet, e.g. which
patients would benefit the most from a treatment with can-
nabinoids and what the appropriate dosages and modes of
application are. Other questions include the risks of long-term
treatment and which group of patients should be excluded
from treatment with cannabinoids.
There is an almost unanimous request in the current literature
to conduct larger clinical trials to find out whether treatment
with Cannabis/cannabinoids could provide benefit to the IBD
patient. Cannabis is still rated as an illegal drug in most countries.
However, because of the high public interest in cannabinoid-
based medication, health-care providers, political institutions,
and funding agencies hopefully will promote these kinds of
studies by providing financial support and by easing legal bar-
riers that still put patients and physicians in a semi-illegal posi-
tion. For the researcher, one thing is certain: apart from THC and
CBD, other anti-inflammatory compounds of the Cannabis plant
are still waiting to be explored offering a vast and promising
research area. However, physicians need definite proof that
Cannabis/cannabinoids are effective in human IBD as well as
guidelines for potential use. Fifty years after the discovery of
THC by Raphael Mechoulam [79], the time is more than ripe.
Key issues
● The GI tract accommodates all the relevant components of
the endocannabinoid system and is therefore highly amen-
able to treatment with Cannabis/cannabinoids
● Preclinical data in mouse models show that Cannabis/can-
nabinoids reduce the severity of colitis and relax intestinal
hypercontractility through cannabinoid receptors and other
components of the endocannabinoid system
● Cannabis/cannabinoids not only act via classical cannabi-
noid receptors but also via GPR55, TRPV1, and PPAR
receptors
● To circumvent side effects of cannabinoid compounds,
levels of endocannabinoids can be raised by inhibitors of
endocannabinoid-degrading enzymes, such as FAAH and
MGL. These enzymes are important drug targets in IBD.
● Translation of preclinical data on cannabinoids in experi-
mental IBD into humans has been insufficiently investigated
warranting large clinical trials
● Cannabis may be helpful in Crohn’s disease to ease abdom-
inal pain but should be only considered after failure of
standard medication and assessment of risks
● Short term treatment with cannabinoids may cause com-
mon adverse effects like dry mouth, fatigue and dizziness
but also serious adverse effects occur.
● Until clinical trials do not provide evidence that IBD patients
will benefit from a treatment with Cannabis/cannabinoids
and before the questions of safety and tolerability are not
solved, treatment with Cannabis/cannabinoids for IBD
should not be recommended
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